Characterization and Prediction of Early Onset Diabetic Peripheral Neuropathy (NeuroPredict)

Characterization and Prediction of Early Onset Diabetic Peripheral Neuropathy (NeuroPredict)

Predicting early onset neuropathy in people with type 1 diabetes

Study Overview

• Status: Recruiting
• Conditions: Type 1 Diabetes; Neuropathy, Diabetic; Small Nerve Fiber Neuropathy
• Intervention / Treatment: Diagnostic test: Thermal perception thresholds; Diagnostic test: Skin biopsies with quantification of intra-epidermal nerve fibre density; Diagnostic test: Perception Threshold Tracking; Diagnostic test: Corneal confocal Microscopy; Diagnostic test: MRI; Diagnostic test: Nerve conduction studies; Other: Composite scores and questionnaires

Detailed Description

Background

Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe courses. Despite the frequent occurrence, the causes of diabetic peripheral neuropathy are largely unknown, which is reflected in the fact that no disease-modifying treatments are available for preventing, treating or even halting the progression of the disease. The consequences can be dire, as neuropathy frequently leads to foot ulcers, amputations or intolerable neuropathic pain in the lower extremities. Sensory loss may go completely undetected in diabetes, as there often are literally no symptoms. For many individuals, the development of diabetic peripheral neuropathy can therefore proceed completely unnoticed, making regular screening the most important tool for diagnosing the condition. Unfortunately, unlike nephropathy or retinopathy, diabetic peripheral neuropathy is not easily screened for, as the condition lacks reliable markers for early- or progressing disease. Therefore, screening for diabetic peripheral neuropathy currently revolves around diagnosing loss of protective sensation, judged by the inability to feel vibration or light touch. However, in their most recent guidelines, the American Diabetes Association has included screening for small fibre neuropathy using either the cold- and heat perception thresholds or pinprick as a clinical standard. Although this acknowledgement of the importance of assessing not only large- but also small nerve fibres is a huge step towards early detection of diabetic peripheral neuropathy, the overriding issue of insensitive, unreproducible, and inaccurate bedside tests for small nerve fibres remains. While cold- and heat perception and pinprick sensation are indeed mediated by small nerve fibres, the sensitivity of these methods, outside of extreme standardization only achievable in dedicated neuropathy research-centres, remain poor and not usable on an individual level. This lack of sensitivity has also become apparent in several large clinical trials, where the methods have continuously failed as robust clinical endpoints. Due to this, the hunt for a sensitive and reproducible method for adequate assessment of the small nerve fibres have begun. Amongst several interesting methods, two have gained particular interest (corneal confocal microscopy and skin biopsies with quantification of intra-epidermal nerve fibre density), due to their diverse strengths, although clinical application is currently limited to a few specialized sites. Furthermore, both methods suffer several inherent issues including that fact that they only provide information about the structure of the nerves and not the function.

In this study, we will therefore combine established gold standards for early detection of structural changes to small nerve fibres in diabetic peripheral neuropathy with cutting-edge, experimental techniques for measuring the function of the same nerve fibres. Furthermore, we will also evaluate several advanced technologies as an alternative to the current clinical standard for large fibre evaluation (biothesiometry).

Study objectives

• To establish a prospective cohort for long-term follow-up for early detection of the development of diabetic peripheral neuropathy
• To evaluate alternative methods for screening for diabetic peripheral neuropathy in a clinical setting
• To evaluate measurements of small nerve fibre function against methods for small nerve fibre structure

Methods

A prospective, long-term, follow-up, cohort study running from 01.04.2022-31.12.2029. The study will consist of two different, yet aligned, sub-studies:

1. An observational, cohort study consisting of a random sample of up to 1,000 persons with diabetes (any type) and neuropathy at any stage, entering the outpatient clinic at Steno Diabetes Center North Denmark/Department of Endocrinology, Aalborg University Hospital.
2. A smaller, observational, cohort study consists of 100-200 persons with type 1 diabetes and no clinically detectable neuropathy.

The first study will aim to evaluate alternative screening methods to be used in clinical practice, while it will also be used to identify persons eligible to participate in the second study.

The second study will aim to preform deep-sensory phenotyping of people without established diabetic peripheral neuropathy using methods evaluating both structure and function of small nerve fibers. The cohort will be followed from inclusion and evaluated once yearly to see if they are progressing. Ultimately, this cohort will be used to retrospectively evaluate, if any, or a combination of, the used experimental methodology can predict, who develops diabetic peripheral neuropathy, and who doesn't.

Participants from either of the two studies will be informed about the trial and their expected outcomes both written and vocally. Participants will follow their usual clinical control for diabetes and complication-screening (including usual foot care and neuropathy screening), and the enhanced screening performed in this study will therefore be an addition to clinical standard. No interventions will be made.

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Johan M Røikjer, PhD; Phone Number: +45 97663651; Email: j.roeikjaer@rn.dk
• Study Contact Backup: Name: Niels Ejskjaer, PhD; Phone Number: +45 +4597663656; Email: n.ejskjaer@rn.dk

Study Locations

• Denmark
  • Aalborg, Denmark, 9000
    • Recruiting
    • Aalborg University Hospital
    • Contact: Johan Røikjer, MD, PhD; Phone Number: +45 97666092

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Type 1 diabetes without established neuropathy with planned continuity of care at Steno Diabetes Center North Denmark, Aalborg

Description

Inclusion Criteria:

• Men and women aged 18-80 years
• Diagnosed with diabetes (of any type)
• No clinically established diabetic peripheral neuropathy at inclusion

Exclusion Criteria:

• Alcohol or drug abuse within the last year (prior to inclusion)
• Chemotherapy (prior or within study period) or experimental medicine
• Severe vitamin deficiencies
• Inability to understand or comply with the examinations
• Planned or likely discontinuation of care at Aalborg University Hospital
• Known hematologic disorders resulting in a markedly reduced ability to stop small bleedings
• Severe limb ischemia
• Active diabetic foot ulcers
• Previous amputations
• Severe skin diseases or diseases known to cause neural damage
• Pregnancy at inclusion

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Type 1 diabetes without known peripheral neuropathy; People with type 1 diabetes without known peripheral neuropathy with "limited" diabetes duration

Diagnostic test: Thermal perception thresholds; Heat and cold perception thresholds; Other Names: Quantitative Sensory Testing; Diagnostic test: Skin biopsies with quantification of intra-epidermal nerve fibre density; Skin biopsy; Other Names: PGP9.5, antibodies for subsets of ion-channels ect; Diagnostic test: Perception Threshold Tracking; Transcutaneous stimulation of large and small nerve fibres using weak electrical currents; Other Names: PTT; Diagnostic test: Corneal confocal Microscopy; Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density; Other Names: CCM; Diagnostic test: MRI; Functional and structural MRI pictures of peripheral nerves and CNS; Other Names: fMRI, DTI, neurography; Diagnostic test: Nerve conduction studies; Nerve conduction and amplitude of Sural nerve; Other Names: NC-STAT DPNCheck; Other: Composite scores and questionnaires; Composite scores and questionnaires; Other Names: DN4, MNSI, NDS, NAFF

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prediction of early onset neuropathy	Retrospective evaluation of the predictive power for each of the diagnostic tests	1,3,5,7,9 years
Comparison of Perception Threshold Tracking (PTT) and skin biopsies	Sensitivity, specificity, PPV, NPV of PTT compared to skin biopsies	1-2 years
Progression and regression of neuropathy	Description of the natural history of the development of neuropathy	1-9 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Development and testing of single-use electrode for PTT	As title states	5 years
Development and testing of new pulse shapes for PTT	As title states	5 years
Correlation between central and peripheral measurements	MRI-scans vs peripheral measurements	1-5 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stability of skin biopsies over time	Repeated analysis of intra-epidermal nerve fibre density in skin biopsies frozen several years	9 years
fMRI as a marker for progression of neuropathy	as title states	9 years

Collaborators and Investigators

• Sponsor: Aalborg University Hospital
• Collaborators: University of Aarhus; Aalborg University
• Investigators: Study Chair: Peter Vestergaard, PhD, Steno Diabetes Center North Denmark; Principal Investigator: Johan M Røikjer, PhD, Steno Diabetes Center North Denmark

Publications and helpful links

Helpful Links

• Steno Diabetes Center North Denmark

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2023
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2029

Study Registration Dates

• First Submitted: September 15, 2022
• First Submitted That Met QC Criteria: September 15, 2022
• First Posted (Actual): September 19, 2022

Study Record Updates

• Last Update Posted (Actual): June 28, 2024
• Last Update Submitted That Met QC Criteria: June 27, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: Diabetic neuropathy, Early detection, Clinical Endpoints, Prediction, Risk stratification
• Additional Relevant MeSH Terms: Nervous System Diseases; Endocrine System Diseases; Diabetes Complications; Diabetes Mellitus; Neuromuscular Diseases; Peripheral Nervous System Diseases; Diabetic Neuropathies; Small Fiber Neuropathy
• Other Study ID Numbers: N-20220013

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No